Anest. intenziv. Med. 2015;26(4):223-227

Vasopressin and its role in anaesthesiology and intensive care medicineSpecial article

M. Balík1,*, V. Černý2, V. Šrámek3, M. Matějovič4, J. Kunstýř1
1 KARIM 1. LF UK a VFN, Praha
2 KARIM Masarykova nemocnice, Ústí nad Labem
3 KAR FN U sv. Anny, Brno
4 1. interní klinika FN PLzeň

Vasopressin has an essential role in the regulation of the vasomotor tone. Its insufficient level plays a substantial role in the pathophysiology of refractory shock associated with sepsis, haemorrhage and extracorporeal circulation. Its role in the control of arterial pressure is emphasised at times when other systems are blocked, not functional, or incapable of maintaining blood pressure - for example in septic shock or in refractory vasoparalysis. A low dose of vasopressin may contribute to normalisation of the vascular tone and perfusion of vital organs.
The indications for vasopressin administration include septic shock with a need for high-dose noradrenaline infu-sion, particularly in patients with myocardial dysfunction and pulmonary hypertension. Vasopressin is indicated not only in vasoparalysis related to sepsis but also due to antihypertensive drug poisoning and in cardiac anaesthesia. Its role is recognized in brain-dead organ donors, portal hypertension and during cardiopulmonary resuscitation.
In contrast to many EU countries, Canada, Australia and New Zealand, the availability of vasopressin in the Czech Republic depends on special delivery which makes it a scarce drug for a critically ill patient who needs the drug urgently. The only available option is its synthetic analogue terlipressin which possesses different pharmacodynamics with a long halftime, and its infusion is rather difficult to operate with a significantly higher number of side effects. Therefore, the registration of vasopressin on the Czech market would be very desirable.

Keywords: vasopressin; septic shock; hypotension; vasoparalysis; portal hypertension; organ donors; cardiopulmonary resuscitation

Received: May 13, 2015; Accepted: May 13, 2015; Published: August 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Balík M, Černý V, Šrámek V, Matějovič M, Kunstýř J. Vasopressin and its role in anaesthesiology and intensive care medicine. Anest. intenziv. Med. 2015;26(4):223-227.
Download citation

References

  1. Russel, J. A. Bench-to-bedside review: Vasopressin in the mana-gement of septic shock. Crit. Care, 2011, 15, p. R226. Go to original source... Go to PubMed...
  2. Landry, D. W., Oliver, J. A. The Pathogenesis of Vasodilatory Shock. N. Engl. J. Med., 2001, 345, 8, p. 588-595. Go to original source... Go to PubMed...
  3. Leone, M., Martin, C. Vasopressor use in septic shock: an update. Curr. Opin. Anesth., 2008, 21, p. 141-147. Go to original source... Go to PubMed...
  4. Russel, J. A., Walley, K. R., Singer, J., Gordon, A. C., Hé-bert, P. C., Cooper, D. J. et al. Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. NEJM, 2008, 358, 9, p. 877-887. Go to original source... Go to PubMed...
  5. Landoni, G., Bove, T., Szekely, A., Comis, M. et al. Reducing mortality in acute kidney injury patients: systematic review and international web-based survey. J. Cardiothorac. Vasc. Anesth., 2013, 27, 6, p. 1384-1398. Go to original source... Go to PubMed...
  6. Gordon, A. C., Russell, J. A., Walley, K. R., Singer, J., Ayers, D., Storms, M. M. et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med., 2010, 36, p. 83-91. Go to original source... Go to PubMed...
  7. De Backer, D., Scolletta Vasopressors in shock: too early to move away from catecholamines? Br. J. Pharmacol., 2012, 165, p. 2012-2014. Go to original source... Go to PubMed...
  8. Jung-Joon, Cha, Chung, H., Won Yoon, Y. et al. Diverse geometric changes related to dynamic left ventricular outflow tract obstruction without overt hypertrophic cardiomyopathy. Cardiovascular Ultrasound, 2014, 12, p. 23. Go to original source... Go to PubMed...
  9. Anger, K. E., Szumia, P. M., Reardon, D. P., DeGrado, J. R. Early vasopressin reduces incidence of new onset arrhythmias. J. Crit. Care, 2014, 29, 4, p. 482-485. Go to original source... Go to PubMed...
  10. Levy, M. M., Rhodes, A., Annane, D. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med., 2013, 39, 2, p. 165-228. Go to original source... Go to PubMed...
  11. Serpa-Neto, A., Nassar, A. P. Jr., Cardoso, S. O. et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care, 2012, 16, R154. Go to original source... Go to PubMed...
  12. Kunstyr, J., Lincova, D., Mourad, M., Lips, M., Cermak, T., Kotulak, T., Blaha, J., Rubes, D., Matias, M., Stritesky, M. A retrospective analysis of Terlipressin infusion in patients with refractory hypotension after cardiac surgery. J. Cardiovasc. Surg.,2008, 49, 3, p. 381-387.
  13. Solanki, P., Chawla, A., Garg, R., Gupta, R., Jain, M., Sa-rin, S. K. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial.J. Journal of Gastroenterology and Hepatology, 2003, 18, p. 152-156. Go to original source... Go to PubMed...
  14. Antonio Paulo Nassar, Jr., Queiroz Farias, A., Augusto Carneiro d' Albuquerque, L., Jose' Carrilho, F., Marcelo Sa' Malbouisson, L. Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. Plos One, 2014, 9, 9, e107466. Go to original source... Go to PubMed...
  15. Plurad, D. S., Neville, A., Bongard, F., Putnam, B. Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors. Am. J. Surg., 2012, 204, 6, p. 856-860. Go to original source... Go to PubMed...
  16. Aung, K., Htay, T. Vasopressin for cardiac arrest: a systematic review and metaanalysis. Arch. Intern. Med., 2005, 165, p. 17-24. Go to original source... Go to PubMed...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.